文献类型：期刊文献

英文题名：N6-methyladenosine RNA modification: an emerging molecule in type 2 diabetes metabolism

作者：Zhang, Haocheng[1,2,3];Gu, Yan[4];Gang, Qiaojian[1];Huang, Jing[5];Xiao, Qian[5];Ha, Xiaoqin[1,2,3]

第一作者：Zhang, Haocheng

通信作者：Ha, X[1];Ha, X[2];Ha, X[3]

机构：[1]Lanzhou Univ, Sch Clin Med 2, Lanzhou, Gansu, Peoples R China;[2]940th Hosp Joint Logist Support Force Chinese Peop, Dept Clin Lab, Lanzhou, Gansu, Peoples R China;[3]Key Lab Stem Cells & Gene Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China;[4]Gansu Agr Univ, Coll Vet Med, Lanzhou, Gansu, Peoples R China;[5]Gansu Univ Tradit Chinese Med, Sch Publ Hlth, Lanzhou, Gansu, Peoples R China

第一机构：Lanzhou Univ, Sch Clin Med 2, Lanzhou, Gansu, Peoples R China

通信机构：[1]corresponding author), Lanzhou Univ, Sch Clin Med 2, Lanzhou, Gansu, Peoples R China;[2]corresponding author), 940th Hosp Joint Logist Support Force Chinese Peop, Dept Clin Lab, Lanzhou, Gansu, Peoples R China;[3]corresponding author), Key Lab Stem Cells & Gene Drugs Gansu Prov, Lanzhou, Gansu, Peoples R China.

年份：2023

卷号：14

外文期刊名：FRONTIERS IN ENDOCRINOLOGY

收录：;Scopus(收录号：2-s2.0-85165295504);WOS:【SCI-EXPANDED(收录号:WOS:001030173000001)】；

基金：Funding This research was funded by Nation Natural Science Foundation of China, grant number 81273568.

语种：英文

外文关键词：insulin resistance; metabolism; m6A modification; signaling pathway; type 2 diabetes

摘要：Type 2 diabetes (T2D) is a metabolic disease with an increasing rate of incidence worldwide. Despite the considerable progress in the prevention and intervention, T2D and its complications cannot be reversed easily after diagnosis, thereby necessitating an in-depth investigation of the pathophysiology. In recent years, the role of epigenetics has been increasingly demonstrated in the disease, of which N6-methyladenosine (m6A) is one of the most common post-transcriptional modifications. Interestingly, patients with T2D show a low m6A abundance. Thus, a comprehensive analysis and understanding of this phenomenon would improve our understanding of the pathophysiology, as well as the search for new biomarkers and therapeutic approaches for T2D. In this review, we systematically introduced the metabolic roles of m6A modification in organs, the metabolic signaling pathways involved, and the effects of clinical drugs on T2D.